Evidence map›Paper›PMID 34835041›Full record

ArticleViruses2021

Epidemiological and Immunological Features of Obesity and SARS-CoV-2.

Eric J Nilles, Sameed M Siddiqui, Stephanie Fischinger, Yannic C Bartsch, Michael de St Aubin, Guohai Zhou, Matthew J Gluck, Samuel Berger, Justin Rhee, Eric Petersen and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Does Obesity Paradox Exist in COVID-19 Mortality?Journal of obesity & metabolic syndrome · 2022
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 8 institutions in 2 countries.

Eric J NillesBrigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0001-7044-5257
Sameed M SiddiquiComputational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Stephanie FischingerRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Yannic C BartschRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Michael de St AubinHarvard Humanitarian Initiative, Boston, MA 02114, USA.ORCID 0000-0003-4833-6200
Guohai ZhouBrigham and Women's Hospital, Boston, MA 02115, USA.
Matthew J GluckSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.ORCID 0000-0001-7732-0481
Samuel BergerSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.
Justin RheeSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.
Eric PetersenSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.
Benjamin MormannBrigham and Women's Hospital, Boston, MA 02115, USA.
Michael LoescheBrigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-0737-0138
Yiyuan HuSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.
Zhilin ChenRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Jingyou YuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Makda GebreRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Caroline AtyeoRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Matthew J GormanRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Alex Lee ZhuRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
John BurkeRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Matthew SleinRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0001-8288-787X
Mohammad A HasdiandaBrigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-3100-9660
Guruprasad JambaulikarBrigham and Women's Hospital, Boston, MA 02115, USA.
Edward W BoyerBrigham and Women's Hospital, Boston, MA 02115, USA.
Pardis C SabetiMassachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
Dan H BarouchBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Boris JulgBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Adam J KucharskiLondon School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
Elon R MuskSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Galit AlterMassachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.
Anil S MenonSpace Exploration Technologies Corp., Hawthorne, CA 90250, USA.ORCID 0000-0002-6886-3553
Ragon Institute of MGH, MIT and Harvard · USBrigham and Women's Hospital · USSpaceX (United States) · USBroad Institute · USHarvard University · USDana-Farber/Harvard Cancer Center · USMassachusetts Institute of Technology · USUniversity of London · GB

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
Mentoring in Advanced mHealth Technologies and Machine Learning for HIV/Drug Abuse ResearchK24DA037109 · NIDA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOYER, EDWARD W · 2014 to 2025
$1.9M
NIDA National Early Warning System Network (iN3): An Innovative ApproachR56DA038366 · NIDA · WRIGHT STATE UNIVERSITY · PI BOYER, EDWARD W, CARLSON, ROBERT GEOFFREY · 2014 to 2014
$300k
Gates Foundation OPP1146996NASA NNX16AO69ANCI NIH HHS U01 CA260476NIAID NIH HHS R01 AI146785NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790NIDA NIH HHS K24 DA037109NIDA NIH HHS R56 DA038366NIH HHS 1U01CA260476NIH HHS 3R37AI080289-11S1NIH HHS CIVIC75N93019C00052NIH HHS INV-001650NIH HHS R01AI146785NIH HHS U19AI135995-02NIH HHS U19AI42790-01Wellcome Trust 206250/Z/17/Z
6 · The paper itself

Abstract

Obesity is a key correlate of severe SARS-CoV-2 outcomes while the role of obesity on risk of SARS-CoV-2 infection, symptom phenotype, and immune response remain poorly defined. We examined data from a prospective SARS-CoV-2 cohort study to address these questions. Serostatus, body mass index, demographics, comorbidities, and prior COVID-19 compatible symptoms were assessed at baseline and serostatus and symptoms monthly thereafter. SARS-CoV-2 immunoassays included an IgG ELISA targeting the spike RBD, multiarray Luminex targeting 20 viral antigens, pseudovirus neutralization, and T cell ELISPOT assays. Our results from a large prospective SARS-CoV-2 cohort study indicate symptom phenotype is strongly influenced by obesity among younger but not older age groups; we did not identify evidence to suggest obese individuals are at higher risk of SARS-CoV-2 infection; and remarkably homogenous immune activity across BMI categories suggests immune protection across these groups may be similar.

Indexed as

AdolescentAdultAge FactorsAntibodies, ViralBody Mass IndexCOVID-19FemaleHumansImmunoglobulin GMaleMiddle AgedObesityRisk FactorsSARS-CoV-2Spike Glycoprotein, CoronavirusYoung AdultAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2body mass indexclinical featuresCOVID-19epidemiologyimmunityobesitySARS-CoV-2

Identifiers

PMID34835041
PMCPMC8624148
OpenAlexW3212908198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.